Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

GU Cancers 2021 | Predicting long-term benefit from ICIs in mUC

Name: Predicting long-term benefit from ICIs in mUC
Uploaded: 2021-02-15T00:00:00Z
Duration: 5 min 1 s

Srikala Sridhar • 15 Feb 2021

GU Cancers 2021

Bladder Cancer Genitourinary Cancer Urothelial Carcinoma Antibodies Checkpoint Inhibitors Durvalumab Tremelimumab

Srikala Sridhar, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, ON, describes a retrospective, post-hoc analysis of two clinical studies (NCT01693562, NCT02261220) evaluating durvalumab, a PD-L1 inhibitor, alone or in combination with tremelimumab, a CTLA-4 inhibitor, in patients with metastatic urothelial carcinoma (mUC). The aim of this study was to identify factors that predict long-term benefit from immune checkpoint inhibitors in mUC. The analysis demonstrated that a number of characteristics, such as tumor response to treatment, were associated with long-term overall survival in this patient group. This interview took place during the 2021 Genitourinary Cancers Symposium.